Skip to main content

Pravastatin Sodium (Monograph)

Drug class: HMG-CoA Reductase Inhibitors

Medically reviewed by Drugs.com on Jul 10, 2024. Written by ASHP.

Introduction

Antilipemic agent; hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (i.e., statin).1 2 3 4 5 6

Uses for Pravastatin Sodium

Reduction in Risk of Cardiovascular Events

Adjunct to diet and lifestyle modifications in adults with elevated LDL-cholesterol without clinical evidence of CHD to reduce the risk of MI, myocardial revascularization procedures, and cardiovascular mortality.1 12

Adjunct to diet and lifestyle modifications in adults with clinical evidence of CHD to reduce the risk of total mortality by reducing coronary death, MI, myocardial revascularization procedures, and stroke or TIA.1 17 29 48 54 65 69

Extensive evidence demonstrates that statins can substantially reduce LDL-cholesterol concentrations and associated risk of atherosclerotic cardiovascular disease (ASCVD) when used for secondary or primary prevention in high-risk patients.336 337 338 400

AHA/ACC cholesterol management guideline states that lifestyle modification is the foundation of ASCVD risk reduction.400 Patients with established ASCVD or high risk of ASCVD should also be treated with a statin.400

Because relative ASCVD risk reduction is correlated with degree of LDL-cholesterol lowering, use maximum tolerated intensity of a statin to achieve greatest benefit.400 High-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by ≥50%) is recommended; if high-intensity statin therapy not possible (e.g., because of a contraindication or intolerable adverse effect), may consider moderate-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by 30–49%).400 AHA/ACC considers pravastatin 40–80 mg daily to be a moderate-intensity statin.400

The addition of a nonstatin drug (e.g., ezetimibe, PCSK9 inhibitor) to statin therapy may be considered in certain high-risk patients who require further reduction in LDL-cholesterol concentrations, particularly if there is evidence from randomized controlled studies suggesting that the addition of the nonstatin drug further reduces ASCVD events.400

When considering whether to initiate statin therapy for primary prevention, AHA/ACC recommends an individualized approach and shared decision making between patient and clinician.400 According to the guidelines, statin therapy may be considered in certain high-risk groups such as adults 20–75 years of age with LDL cholesterol ≥190 mg/dL, adults 40–75 years of age with diabetes mellitus, adults 40–75 years of age without diabetes mellitus but with LDL-cholesterol levels ≥70 mg/dL and an estimated 10-year ASCVD risk ≥7.5%, and adults 40–75 years of age with chronic kidney disease (not treated with dialysis or transplantation) and LDL-cholesterol concentrations of 70–189 mg/dL who have a 10-year ASCVD risk ≥7.5%.400

Dyslipidemias

Adjunct to nondrug therapies (e.g., dietary management) in adults to decrease elevated LDL-cholesterol concentrations in the treatment of adults with primary hyperlipidemia.1 2 3 5 17

Adjunct to dietary therapy to reduce LDL-cholesterol in children ≥8 years of age with heterozygous familial hypercholesterolemia.1

Adjunct to nondrug therapies (e.g., dietary management) in the treatment of adults with primary dysbetalipoproteinemia.1

Adjunct to nondrug therapies (e.g., dietary management) in the treatment of adults with hypertriglyceridemia.1

Pravastatin Sodium Dosage and Administration

General

Pretreatment Screening

Patient Monitoring

Administration

Administer orally at any time of day without regard to meals.1

Dosage

Dosage modifications may be necessary when used concomitantly with certain drugs.1

Pediatric Patients

Dyslipidemias
Oral

Children 8–13 years of age: 20 mg once daily.1 Dosages >40 mg daily have not been evaluated.1

Adolescents 14–18 years of age: 40 mg once daily.1 Dosages >40 mg daily have not been evaluated.1

Adults

Reduction in Risk of Cardiovascular Events
Oral

Initially, 40–80 mg once daily.1 Use maximally tolerated statin intensity to achieve optimal ASCVD risk reduction.400 High-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by ≥50%) is preferred; if high-intensity statin therapy not possible (e.g., because of a contraindication or intolerable adverse effect), may consider moderate-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by 30–49%).400

The AHA/ACC guideline panel considers pravastatin 40–80 mg daily to be a moderate-intensity statin.400

Dyslipidemias
Oral

Initially, 40 or 80 mg once daily.1 Adjust dosage at intervals of ≥4 weeks until the desired effect on lipoprotein concentrations is observed.1

Special Populations

Hepatic Impairment

No specific dosage recommendations.1

Renal Impairment

Initially, 10 mg once daily in patients with severe renal impairment; maximum dosage 40 mg once daily.1

Geriatric Patients

No specific dosage recommmendations.1 Cautious dose selection recommended.1

Pharmacogenomic Considerations

SLCO1B1 poor function phenotype: Initial dosage ≤40 mg/day.500

Detailed Pravastatin dosage information

Cautions for Pravastatin Sodium

Contraindications

Warnings/Precautions

Musculoskeletal Effects

Myopathy (manifested as muscle pain, tenderness, or weakness and serum creatine kinase [CK] concentration increases) reported occasionally.1

Rhabdomyolysis (characterized by muscle pain, tenderness, or weakness with marked increases [>10 times the ULN] in serum CK concentrations and increases in Scr with acute renal failure secondary to myoglobinuria has been reported.1

Risk of myopathy is increased in patients receiving higher dosages of statins; risk also may be increased in geriatric patients (≥65 years of age) and patients with renal impairment or uncontrolled hypothyroidism.1

Certain drug interactions also may increase risk of myopathy and/or rhabdomyolysis.1

AHA/ACC recommends measurement of CK levels in patients with severe statin-associated muscle symptoms; however, routine monitoring not useful.400

Consider myopathy in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation in CK.1 Discontinue if serum CK concentrations increase markedly or if myopathy is diagnosed or suspected.1

Temporarily withhold therapy in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; uncontrolled seizures).1

Advise patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.1

Immune-mediated Necrotizing Myopathy

Immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, reported rarely.1 Characterized by proximal muscle weakness and elevated CK concentrations that persist despite discontinuance of statin therapy, positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement following therapy with immunosuppressive agents.1 Discontinue pravastatin if IMNM suspected.1

Hepatic Effects

Associated with increases in serum aminotransferase (AST, ALT) concentrations.1

Rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including pravastatin.1

Consider liver enzyme tests before initiation of therapy and as clinically indicated.1 Serious statin-related liver injury is rare and unpredictable, and routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing serious liver injury.200 AHA/ACC cholesterol management guideline states that it is reasonable to obtain liver function tests in patients with symptoms of hepatotoxicity (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine, yellowing of skin or sclera); however, routine monitoring not recommended.200 400

Use with caution in patients who consume substantial amounts of alcohol and/or have a history of liver disease.1 Contraindicated in patients with acute liver failure or decompensated cirrhosis.1

If serious liver injury with clinical manifestations and/or hyperbilirubinemia or jaundice occurs, promptly interrupt pravastatin therapy.1

Hyperglycemic Effects

Increases in HbA1c and fasting serum glucose concentrations reported.200 Possible increased risk of developing diabetes.1 200

AHA/ACC cholesterol management guideline states that in patients with increased risk of diabetes mellitus or new-onset diabetes mellitus, statin therapy and lifestyle modifications should be continued to reduce risk of ASCVD.400

Specific Populations

Pregnancy

All statins were previously contraindicated in pregnant women because fetal risk was thought to outweigh any possible benefit.405 However, the totality of evidence to date indicates limited potential for statins to cause malformations and other adverse embryofetal effects; FDA has therefore requested removal of the contraindication.405 Most pregnant patients should still discontinue statins because of the possibility of fetal harm; however, some patients (e.g., those with homozygous familial hypercholesterolemia or established cardiovascular disease) may benefit from continued therapy.400 402 405 Consider patient's individual risks and benefits.402 405

Patients who become pregnant or suspect that they are pregnant while receiving a statin should notify their clinician; clinician should advise patient on the appropriate course of action.405

Increased risk of miscarriage reported in pregnant women exposed to statins; however, not clear whether drug-related or due to other confounding factors.400 405

Lactation

Distributed into human milk; effects of drug on breast-fed infants or milk production not known.1 Use not recommended in nursing women; women who require pravastatin therapy should not breast-feed their infants.1 Many patients can stop statin therapy temporarily until breast-feeding is complete; patients who require ongoing statin treatment should not breast-feed and should use alternatives such as infant formula.400 402 405

Females and Males of Reproductive Potential

AHA/ACC cholesterol management guideline states women (including adolescents) of childbearing age who are sexually active should be counseled to use a reliable form of contraception.400

Pediatric Use

Safety and effectiveness in pediatric patients ≥8 years of age with heterozygous familial hypercholesterolemia (HeFH) established.1 Dosages >40 mg daily not studied in this population.1

Safety and efficacy not evaluated in pediatric patients with other types of hyperlipidemia.1

Geriatric Use

No substantial differences in safety or efficacy relative to younger adults.1

Use with caution, since age ≥65 years is a predisposing factor for myopathy.1

Patients >75 years of age may have a higher risk of adverse effects and lower adherence to therapy; consider expected benefits versus adverse effects before initiating statin therapy in this population.400

Hepatic Impairment

Use with caution in patients who consume substantial amounts of alcohol and/or have a history of liver disease.1

Contraindicated in patients with active liver failure or decompensated cirrhosis.1

Renal Impairment

Monitor closely for adverse musculoskeletal effects, since history of renal impairment may be a risk factor for development of rhabdomyolysis.1

Dosage adjustments necessary in patients with severe renal impairment.1

Pharmacogenomic Considerations

Genetic variation in the solute carrier organic anion transporter (SLCO) family member (SLCO1B1), ABCG2 (also known as breast cancer resistance protein [BCRP]), and CYP2C9 genes alter systemic exposure to statins, which can increase the risk for statin-associated musculoskeletal symptoms.500

In patients with phenotypes that result in increased statin exposure, consider other patient-specific issues that may increase statin exposure (e.g., renal and hepatic function, drug-drug interactions).500

Experts state statin therapy should neither be discontinued nor avoided based on SLCO1B1, ABCG2, or CYP2C9 genotype results for patients with an indication for statin therapy.500

Patients with SLCO1B1 decreased, possible decreased, or poor function phenotypes will have increased exposure and risk of statin-associated musculoskeletal symptoms.500

Common Adverse Effects

Common adverse effects (≥2% and more than placebo): musculoskeletal pain, nausea/vomiting, upper respiratory infection, diarrhea, headache.1

Drug Interactions

Does not undergo CYP metabolism; pharmacokinetic interaction unlikely.1

Substrate of organic anion transporter protein (OATP) 1B1, 1B3, and 2B1.339 501 502

Drugs Affecting or Affected by Transport Systems

OATP1B1, 1B3, or 2B1 inhibitors: Possible increased exposure and increased risk of statin-induced toxicity (e.g., myopathy).501 502

Specific Drugs

Drug

Interaction

Comments

Antacid liquid

Decreased pravastatin peak plasma concentration and AUC1

Aspirin

Slightly increased pravastatin peak plasma concentration and AUC1

Bile acid sequestrants (i.e., cholestyramine, colestipol)

Variable effects on pravastatin concentrations1

Administer pravastatin at least 1 hour before or at least 4 hours after the sequestrant1

Calcium-channel blocking agents (diltiazem, verapamil)

Increased pravastatin peak plasma concentration and AUC1

Some experts state a non-CYP3A4-metabolized statin (i.e., pravastatin) is preferred339

Cimetidine

Increased pravastatin peak plasma concentration and AUC1

Colchicine

Myopathy, including rhabdomyolysis, reported1

Use concomitantly with caution1 Monitor for signs and symptoms of myopathy, particularly during initiation and upward dose titration1

Cyclosporine

Substantially increased pravastatin peak plasma concentrations and AUC; possible increased risk of myopathy or rhabdomyolysis1 339

If used concomitantly, initiate pravastatin at 10 mg daily; do not exceed pravastatin dosage of 20 mg daily1

Digoxin

Slight increases in plasma digoxin and pravastatin peak plasma concentrations and AUC1

Fibric acid derivatives (e.g., fenofibrate, gemfibrozil)

Increased risk of myopathy or rhabdomyolysis1

Gemfibrozil: Decreased pravastatin peak plasma concentration and AUC1

Gemfibrozil: Avoid concomitant use1

Other fibric acid derivatives (e.g., fenofibrate): Use concomitantly with caution and only if benefits outweigh risks1 Monitor for signs and symptoms of myopathy, particularly during initiation and upward dose titration1

Fluconazole

Decreased pravastatin peak plasma concentration and AUC1

Grapefruit juice

Slight increase in pravastatin peak plasma concentration and slightly decreased AUC1

HIV protease inhibitors

Ritonavir-boosted darunavir: Increased pravastatin peak plasma concentration and AUC1

Lopinavir/ritonavir: Increased pravastatin peak plasma concentration and AUC1

Ritonavir-boosted darunavir: Some experts recommend using the lowest necessary dosage of pravastatin and carefully monitoring patients503

Lopinavir/ritonavir: Some experts recommend using the lowest necessary dosage of pravastatin and carefully monitoring patients503

Itraconazole

Increased pravastatin peak plasma concentrations and AUC1

Macrolides (e.g., azithromycin. clarithromycin, erythromycin)

Azithromycin: Potential increased pravastatin concentrations1

Clarithromycin: Increased pravastatin peak plasma concentration and AUC;1 increased risk of myopathy or rhabdomyolysis1

Erythromycin: Potential increased pravastatin concentrations and increased risk of myopathy1

Azithromycin: Use concomitantly with caution; some experts state azithromycin may be acceptable1 502

Erythromycin or clarithromycin: Use concomitantly with caution; if used concomitantly, do not exceed pravastatin dosage of 40 mg daily1

Niacin

Decreased pravastatin peak plasma concentration and AUC;1 possible increased risk of myopathy1

Use concomitantly with caution and only if benefits outweigh risks; monitor for signs and symptoms of myopathy, particularly during initiation and upward dose titration1

Warfarin

Increased warfarin peak plasma concentration and AUC; increased PT1

Bleeding and/or increased PT/INR observed with other statins339

Monitor INR more closely after initiating or changing dosage of pravastatin339
Pravastatin drug interactions (more detail)

Pravastatin Sodium Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed following oral administration; undergoes extensive first-pass metabolism in the liver.1 129 130 131 132 Mean peak plasma concentrations occur at 1–1.5 hours.1

Absolute bioavailability is 17%.1 130 501

Evening administration of the drug is associated with a decrease in the extent of absorption;1 however, the antilipemic activity remains unchanged and may be superior to the activity achieved with morning administration.1

Onset

Therapeutic response is usually apparent within 1 week after initiating therapy, with a maximal response occurring within 4 weeks.1 37 38 132

Food

Food appears to reduce the systemic bioavailability of pravastatin;1 129 131 however, antilipemic effects are similar whether pravastatin is administered with or 1 hour prior to meals.1

Distribution

Extent

Distributed mainly to the liver.1

Distributed into human milk.1

Plasma Protein Binding

Approximately 50%.1

Elimination

Metabolism

Undergoes isomerization and hydroxylation independent of the CYP enzyme system.1 One metabolite has 1/10th–1/40th the HMG-CoA reductase inhibitory activity of the parent compound.1

Elimination Route

Excreted in urine (20%) and feces (70%).1 129 130 132

Half-life

1.8 hours.1

Special Populations

Renal impairment may reduce clearance of pravastatin and/or active metabolites.1

Hepatic impairment may reduce clearance of pravastatin and/or active metabolites.1

Exposure may be increased in geriatric individuals compared with younger adults.1

Patients with certain solute carrier organic anion transporter (SLCO) 1B1 phenotypes (i.e., decreased, possible decreased, or poor function) will have increased pravastatin exposure compared to those with normal function.500

Stability

Storage

Oral

Tablets

20-25°C in tight containers; protect from light and moisture.1

Actions

Advice to Patients

Additional Information

The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Pravastatin Sodium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

10 mg*

Pravastatin Sodium Tablets

20 mg*

Pravastatin Sodium Tablets

40 mg*

Pravastatin Sodium Tablets

80 mg*

Pravastatin Sodium Tablets

AHFS DI Essentials™. © Copyright 2025, Selected Revisions July 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

1. Teva Pharmaceuticals. Pravastatin sodium tablets prescribing information. Parsippany, NJ; 2024 Jan.

2. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991; 42:65-89. https://pubmed.ncbi.nlm.nih.gov/1718686

3. Anon. Pravastatin, simvastatin, and pravastatin for lowering serum cholesterol concentrations. Med Lett Drugs Ther. 1992; 34:57-8. https://pubmed.ncbi.nlm.nih.gov/1593973

4. Rosen T, Heathcock CH. The synthesis of mevinic acids. Tetrahedron. 1986; 42:4909-51.

5. Raasch RH. Pravastatin sodium, a new HMG-CoA reductase inhibitor. DICP. 1991; 25:388-94. https://pubmed.ncbi.nlm.nih.gov/1926908

6. Serajuddin ATM, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, pravastatin, mevastatin, and simvastatin. J Pharm Sci. 1991; 80:830-4. https://pubmed.ncbi.nlm.nih.gov/1800703

8. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem. 1977; 46:897-930. https://pubmed.ncbi.nlm.nih.gov/197883

9. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest. 1983; 72:743-7. https://pubmed.ncbi.nlm.nih.gov/6309907

12. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-7. https://pubmed.ncbi.nlm.nih.gov/7566020

13. Byington RP, Jukema JW, Salonen JT et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995; 92:2419-25. https://pubmed.ncbi.nlm.nih.gov/7586340

14. Pitt B, Mancini GBJ, Ellis SG et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995; 26:1133-9. https://pubmed.ncbi.nlm.nih.gov/7594023

15. Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995; 75:455-9. https://pubmed.ncbi.nlm.nih.gov/7863988

16. Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995; 91:2528-40. https://pubmed.ncbi.nlm.nih.gov/7743614

17. Sacks FN, Pfeffer MA, Maye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9. https://pubmed.ncbi.nlm.nih.gov/8801446

22. Haria M, McTavish D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs. 1997; 53:299-336. https://pubmed.ncbi.nlm.nih.gov/9028747

23. Rubenfire M, Maciejko JJ, Blevins RD et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med. 1991; 151:2234-40. https://pubmed.ncbi.nlm.nih.gov/1953228

24. Knipscheer HC, Boelen CCA, Kastelein JJP et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Ped Res. 1996; 39:867-71.

25. Glasser SP, DiBianco R, Effron BA et al. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol >160 mg/dL. Am J Cardiol. 1996; 77:83-5. https://pubmed.ncbi.nlm.nih.gov/8540464

26. Salonen R, Nyyssonen K, Porkkala-Sarataho E et al. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995; 76:34-9C.

27. DeGroot E, Jukema JW, Montauban AD et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998; 31:1561-7. https://pubmed.ncbi.nlm.nih.gov/9626835

28. Dangas G, Badimon JJ, Smith DA et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 1999; 33:1294-304. https://pubmed.ncbi.nlm.nih.gov/10193730

29. White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000; 343:317-26. https://pubmed.ncbi.nlm.nih.gov/10922421

32. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, pravastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81:582-7. https://pubmed.ncbi.nlm.nih.gov/9514454

33. Weir MR, Berger ML, Weeks ML et al. Comparison of the effects on quality of life and of the efficacy and tolerability of pravastatin versus pravastatin. Am J Cardiol. 1996; 77:475-9. https://pubmed.ncbi.nlm.nih.gov/8629587

34. Bertolini S, Bon GB, Campbell LM et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997; 130:191-7. https://pubmed.ncbi.nlm.nih.gov/9126664

35. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med. 1993; 153:1321-9. https://pubmed.ncbi.nlm.nih.gov/8507122

36. Mostaza JM, Schulz I, Vega GL et al. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol. 1997; 79:1298-301. https://pubmed.ncbi.nlm.nih.gov/9164913

37. Crepaldi D, Baggio G, Arca M et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia: the Italian Multicenter Pravastatin Study I. Arch Intern Med. 19990; 151:146-52.

38. Betteridge DJ, Bhatnager D, Bing RF et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ. 1992; 23:304:1335-8.

39. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9. https://pubmed.ncbi.nlm.nih.gov/7968073

40. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? Br Med J. 1992; 304:431-4. Editorial.

41. O’Keefe JH, Harris WS, Nelson J et al. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995; 76:480-4. https://pubmed.ncbi.nlm.nih.gov/7653448

42. Gardner SF, Marx MA, White LM et al. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother. 1997; 31:677-82. https://pubmed.ncbi.nlm.nih.gov/9184704

44. McPherson R, Bedard J, Connelly P et al. Comparison of the short-term efficacy and tolerability of pravastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther. 1992; 14:276-91. https://pubmed.ncbi.nlm.nih.gov/1611649

45. Wiklund O, Angelin B, Bergman M et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993; 94:13-20. https://pubmed.ncbi.nlm.nih.gov/8420296

46. Davignon J, Roederer G, Montigny M et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994; 73:339-45. https://pubmed.ncbi.nlm.nih.gov/8109547

47. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol. 1993; 71:1408-14. https://pubmed.ncbi.nlm.nih.gov/8517385

48. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57. https://pubmed.ncbi.nlm.nih.gov/9841303

49. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med. 1998; 129:681-9. https://pubmed.ncbi.nlm.nih.gov/9841599

50. Lewis SJ, Sacks FM, Mitchell JS et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial. J Am Coll Cardiol. 1998; 32:120-6.

52. Flaker GC, Warnica JW, Sacks FM et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol. 1999; 34:106-12. https://pubmed.ncbi.nlm.nih.gov/10399998

54. Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study. Circulation. 1999; 99:216-23. https://pubmed.ncbi.nlm.nih.gov/9892586

56. Simons LA, Nestel PJ, Clifton P et al. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years. Med J Aust. 1992; 157:584-9. https://pubmed.ncbi.nlm.nih.gov/1406416

57. MacMahon S, Sharpe N, Gamble G et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID atherosclerosis substudy. Circulation. 1998; 97:1784-90. https://pubmed.ncbi.nlm.nih.gov/9603532

58. Morimoto S, Koh E, Fukuo K et al. Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia. Clin Ther. 1994; 16:793-803. https://pubmed.ncbi.nlm.nih.gov/7859238

59. Mellies MJ, DeVault AR, Kassler-Taub K et al. Pravastatin experience in elderly and non-elderly patients. Atherosclerosis. 1993; 101:97-110. https://pubmed.ncbi.nlm.nih.gov/8216507

60. Tamura A, Mikuriya Y, Nasu M for the Coronary Artery Regression Study (CARS) Group. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dL and angiographically documented coronary artery disease. Am J Cardiol. 1997; 79:893-6. https://pubmed.ncbi.nlm.nih.gov/9104901

61. Pitsavos CE, Aggeli KI, Barbetseas JD et al. Effects of pravastatin on thoracic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1998; 82:1484-8. https://pubmed.ncbi.nlm.nih.gov/9874052

65. Anon. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 2001; 43:43-8. https://pubmed.ncbi.nlm.nih.gov/11378632

67. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288:2998-3007. https://pubmed.ncbi.nlm.nih.gov/12479764

68. Pasternak RC. The ALLHAT lipid lowering trial—less is less. JAMA. 2002; 288:3042-4. https://pubmed.ncbi.nlm.nih.gov/12479771

69. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-504. https://pubmed.ncbi.nlm.nih.gov/15007110

70. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291: 1071-80. https://pubmed.ncbi.nlm.nih.gov/14996776

120. Waters D, Higginson L, Gladstone P et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation. 1995; 92:2404-10.

121. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-98. https://pubmed.ncbi.nlm.nih.gov/2215615

122. Furberg CD, Adams HP, Applegate WB et al for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994; 90:1679-87. https://pubmed.ncbi.nlm.nih.gov/7734010

124. Glorioso N, Troffa C, Filigheddu F et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999; 34:1281-6. https://pubmed.ncbi.nlm.nih.gov/10601131

125. Borghi C, Prandin MG, Costa FV et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000; 35:549-55. https://pubmed.ncbi.nlm.nih.gov/10774784

126. Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999; 100:230-5. https://pubmed.ncbi.nlm.nih.gov/10411845

127. Kluft C, de Maat MPM, Leuven JAG et al. Statins and C-reactive protein. Lancet. 1999; 353:1274-5.

129. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994; 73:3-11D.

130. Desager JP, Horsmans. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 1996; 31:348-71. https://pubmed.ncbi.nlm.nih.gov/9118584

131. Corsini A, Besllosta S, Baetta R et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999; 84:413-28. https://pubmed.ncbi.nlm.nih.gov/10665838

132. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet. 1997; 32:403-25. https://pubmed.ncbi.nlm.nih.gov/9160173

200. Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. Rockville, MD; 2012 Feb 28. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm

309. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372:2387-97. https://pubmed.ncbi.nlm.nih.gov/26039521

336. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380:581-90. https://pubmed.ncbi.nlm.nih.gov/22607822

337. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-78. https://pubmed.ncbi.nlm.nih.gov/16214597

338. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670-81. https://pubmed.ncbi.nlm.nih.gov/21067804

339. Wiggins BS, Saseen JJ, Page RL et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016; 134:e468-e495.

353. ACCORD Study Group, Ginsberg HN, Elam MB et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563-74. https://pubmed.ncbi.nlm.nih.gov/20228404

354. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al.. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15;365(24):2255-67.

369. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371:203-12. https://pubmed.ncbi.nlm.nih.gov/25014686

371. Anderson TJ, Boden WE, Desvigne-Nickens P et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014; 371:288-90. https://pubmed.ncbi.nlm.nih.gov/25014706

375. Weng TC, Yang YH, Lin SJ et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010; 35:139-51. https://pubmed.ncbi.nlm.nih.gov/20456733

400. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139:e1082-e1143. https://pubmed.ncbi.nlm.nih.gov/30586774

401. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218.

402. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. Epub 2023 Jul 20. Erratum in: Circulation. 2023 Sep 26;148(13):e148. Erratum in: Circulation. 2023 Dec 5;148(23):e186.

403. Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418.

404. Wiegman A, Gidding SS, Watts GF, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21;36(36):2425-37.

405. US Food and Drug Administration. FDA Drug Safety Communication: FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. Silver Spring, MD; 2021 July 20. From FDA website. Accessed 2024 Apr 24. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy

406. Cheeley MK, Saseen JJ, Agarwala A et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022; 16:361-375.

500. Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021.

501. Sadowska A, Osiński P, Roztocka A, Kaczmarz-Chojnacka K, Zapora E, Sawicka D, Car H. Statins-From Fungi to Pharmacy. Int J Mol Sci. 2023 Dec 29;25(1):466.

502. Balasubramanian R, Maideen NMP. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview. Curr Drug Metab. 2021;22(5):328-341.

503. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. (February 27, 2024). Accessed 2024 Apr 18. Available at HIV.gov. https://clinicalinfo.hiv.gov/en/guidelines

Frequently asked questions

Medical Disclaimer